Funding for this research was provided by:
National Institutes of Health (R01 CA234018, U01 CA226196)
Received: 7 April 2020
Accepted: 15 September 2020
First Online: 15 October 2020
Ethics approval and consent to participate
: All animal procedures were carried out under the DFCI Institutional Animal Care and Use Committee (IACUC) protocol and were in accordance with the IACUC standards for the welfare of animals.
: Not applicable.
: XSL is a cofounder, board, and SAB member of GV20 Oncotherapy and its subsidiaries; SAB of 3DMed Care; consultant for Genentech; and stock holder of BMY, TMO, WBA, ABT, ABBV, and JNJ, and received research funding from Takeda and Sanofi.MB is a consultant to and receives sponsored research support from Novartis. MB is a consultant to and serves on the scientific advisory boards of Kronos Bio, H3 Biomedicine, and GV20 Oncotherapy.GJF has patents/pending royalties on the PD-1/PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis. GJF has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, and GV20. GJF has equity in Nextpoint, Triursus, Xios, iTeos, IgM, and GV20.